CN101189257A - 脂质运载蛋白 - Google Patents

脂质运载蛋白 Download PDF

Info

Publication number
CN101189257A
CN101189257A CNA2006800153195A CN200680015319A CN101189257A CN 101189257 A CN101189257 A CN 101189257A CN A2006800153195 A CNA2006800153195 A CN A2006800153195A CN 200680015319 A CN200680015319 A CN 200680015319A CN 101189257 A CN101189257 A CN 101189257A
Authority
CN
China
Prior art keywords
seq
polypeptide
nucleic acid
insp181
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800153195A
Other languages
English (en)
Chinese (zh)
Inventor
M·优克-史密斯
C·鲍尔
U·博斯切特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ares Trading SA
Original Assignee
Ares Trading SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading SA filed Critical Ares Trading SA
Publication of CN101189257A publication Critical patent/CN101189257A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
CNA2006800153195A 2005-03-08 2006-03-08 脂质运载蛋白 Pending CN101189257A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0504767.5 2005-03-08
GBGB0504767.5A GB0504767D0 (en) 2005-03-08 2005-03-08 Lipocalin protein

Publications (1)

Publication Number Publication Date
CN101189257A true CN101189257A (zh) 2008-05-28

Family

ID=34452020

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800153195A Pending CN101189257A (zh) 2005-03-08 2006-03-08 脂质运载蛋白

Country Status (15)

Country Link
US (1) US20080254035A1 (enExample)
EP (1) EP1869074A1 (enExample)
JP (1) JP4933527B2 (enExample)
KR (1) KR20070118614A (enExample)
CN (1) CN101189257A (enExample)
AU (1) AU2006221859B2 (enExample)
BR (1) BRPI0609020A2 (enExample)
CA (1) CA2599540A1 (enExample)
EA (1) EA011816B1 (enExample)
GB (1) GB0504767D0 (enExample)
IL (1) IL185547A0 (enExample)
MX (1) MX2007010809A (enExample)
NO (1) NO20075068L (enExample)
UA (1) UA94221C2 (enExample)
WO (1) WO2006095164A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105008393A (zh) * 2012-12-10 2015-10-28 弗莱德哈钦森癌症研究中心 用于筛选的方法
CN111979249A (zh) * 2020-07-28 2020-11-24 复旦大学附属眼耳鼻喉科医院 一种特异性结合脂质运载蛋白-1的核酸适配体及其应用

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1877428B1 (en) 2005-04-22 2011-03-16 University of Washington Cyanine- chlorotoxin conjugate and method for intra-operative visualization of cancer
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
JP5781762B2 (ja) 2007-08-10 2015-09-24 プロテリックス、インク ユニバーサルｉｉｉ型フィブロネクチン結合ドメインのライブラリ
BRPI0912683A2 (pt) 2008-05-15 2016-01-26 Transmolecular Inc tratamento de tumores metastáticos
CN107056951A (zh) 2008-10-02 2017-08-18 阿帕特夫研究和发展有限公司 Cd86拮抗物多靶点结合蛋白
WO2011079308A2 (en) 2009-12-23 2011-06-30 Emergent Product Development Seattle, Llc Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
NZ600820A (en) 2009-12-29 2014-12-24 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
CN106995493B (zh) 2010-02-04 2021-09-24 卫材公司 氯毒素多肽和结合物及其应用
ES2601182T3 (es) 2010-05-11 2017-02-14 Fred Hutchinson Cancer Research Center Variantes de clorotoxina, conjugados y métodos para su utilización
CA2808392C (en) * 2010-08-16 2020-03-10 Pieris Ag Binding proteins for hepcidin
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
RU2673153C2 (ru) 2012-04-20 2018-11-22 АПТЕВО РИСЁРЧ ЭНД ДИВЕЛОПМЕНТ ЭлЭлСи Полипептиды, связывающиеся с cd3
WO2014152832A1 (en) 2013-03-14 2014-09-25 Immusoft Corporation Methods for in vitro memory b cell differentiation and transduction with vsv-g pseudotyped viral vectors
WO2015017214A1 (en) 2013-07-29 2015-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
SG11201603228TA (en) 2013-10-31 2016-05-30 Hutchinson Fred Cancer Res Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
PT3083671T (pt) 2013-12-20 2020-12-24 Hutchinson Fred Cancer Res Moléculas efetoras quiméricas etiquetadas e recetores destas
WO2015095553A1 (en) * 2013-12-20 2015-06-25 Nephrogenesis, Llc Methods and apparatus for kidney dialysis
JP5866053B1 (ja) * 2014-12-15 2016-02-17 株式会社ファンケル 皮膚粘弾性のマーカー及びその利用
EP3234107B1 (en) 2014-12-19 2022-09-14 Immusoft Corporation B cells for in vivo delivery of therapeutic agents
SG10201908203SA (en) 2015-03-05 2019-10-30 Hutchinson Fred Cancer Res Immunomodulatory Fusion Proteins And Uses Thereof
US20180355318A1 (en) 2015-04-29 2018-12-13 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
US11827904B2 (en) 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
EP4166161A1 (en) 2016-04-14 2023-04-19 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer
WO2018151836A1 (en) 2017-02-17 2018-08-23 Fred Hutchinson Cancer Research Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
WO2018170475A1 (en) 2017-03-17 2018-09-20 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
MA51157A (fr) 2017-12-14 2020-10-21 Bluebird Bio Inc Récepteurs de l'interleukine darique
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
EP3849565A4 (en) 2018-09-12 2022-12-28 Fred Hutchinson Cancer Research Center REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
US12291560B2 (en) 2018-12-14 2025-05-06 Regeneron Pharmaceuticals, Inc. Dimerizing agent regulated immunoreceptor complexes
WO2020227073A1 (en) 2019-05-04 2020-11-12 Inhibrx, Inc. Clec12a-binding polypeptides and uses thereof
JP2022532556A (ja) 2019-05-08 2022-07-15 ２セブンティ バイオ インコーポレイテッド Ｃｌｌ－１標的免疫療法
CN114729383A (zh) 2019-07-02 2022-07-08 弗莱德哈钦森癌症研究中心 重组ad35载体及相关基因疗法改进
US20230312753A1 (en) 2020-05-04 2023-10-05 Immunorizon Ltd. Precursor tri-specific antibody constructs and methods of use thereof
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2025245169A1 (en) 2024-05-21 2025-11-27 Fred Hutchinson Cancer Center Immunotherapy cells equipped with a collagen-targeting payload

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU218717B (hu) * 1989-03-17 2000-11-28 E. I. Du Pont De Nemours And Co. Nukleinsav-termelést fokozó növényi eredetű génfragmentek és eljárás előállításukra
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5362865A (en) * 1993-09-02 1994-11-08 Monsanto Company Enhanced expression in plants using non-translated leader sequences
US5693506A (en) * 1993-11-16 1997-12-02 The Regents Of The University Of California Process for protein production in plants
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20020137159A1 (en) * 2000-08-31 2002-09-26 Si Lok Human phermone polypeptides

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105008393A (zh) * 2012-12-10 2015-10-28 弗莱德哈钦森癌症研究中心 用于筛选的方法
CN111979249A (zh) * 2020-07-28 2020-11-24 复旦大学附属眼耳鼻喉科医院 一种特异性结合脂质运载蛋白-1的核酸适配体及其应用

Also Published As

Publication number Publication date
EA011816B1 (ru) 2009-06-30
AU2006221859B2 (en) 2011-09-22
WO2006095164A1 (en) 2006-09-14
CA2599540A1 (en) 2006-09-14
JP2008536483A (ja) 2008-09-11
JP4933527B2 (ja) 2012-05-16
AU2006221859A1 (en) 2006-09-14
MX2007010809A (es) 2007-11-07
KR20070118614A (ko) 2007-12-17
UA94221C2 (en) 2011-04-26
BRPI0609020A2 (pt) 2016-11-29
NO20075068L (no) 2007-12-10
EP1869074A1 (en) 2007-12-26
US20080254035A1 (en) 2008-10-16
GB0504767D0 (en) 2005-04-13
IL185547A0 (en) 2008-01-06
EA200701918A1 (ru) 2008-02-28

Similar Documents

Publication Publication Date Title
JP4933527B2 (ja) リポカリンタンパク質
US20080196113A1 (en) Lipocalin Protein
WO2008015380A2 (en) Integral membrane protein of the pmp-22/emp/mp20/ claudin-like family
JP2005528336A (ja) シスチン−ノットフォールドタンパク質
EP1904523A1 (en) Defensin proteins
CN101115767A (zh) 包含vWFA和/或ANT_IG结构域的蛋白质
JP4999688B2 (ja) 細胞表面糖タンパク質
EP1802653B1 (en) Mam domain containing protein
HK1120048A (en) Lipocalin protein
JP2005500012A (ja) 核内ホルモンレセプターリガンド結合ドメイン
US20100048467A1 (en) Cystine-Knot Fold Cytokine
WO2007148063A1 (en) Cd24-like protein
JP2003532412A (ja) 新規セリン−トレオニン・キナーゼ−４
WO2007068913A2 (en) SRCR-B Domain Containing Proteins
JP2003525632A (ja) 肝臓で発現するヒトａｂｃトランスポーターａｔｉｌ
WO2007060425A1 (en) Thrombospondin domain-containing cell surface recognition molecules
WO2007060423A1 (en) Signal anchored protein
WO2008017831A1 (en) Secreted vit domain containing proteins
JP2004504060A (ja) リング・フィンガー・ドメイン・ｒ１ｐ４含有新規タンパク質
WO2007060431A1 (en) Netrin-like (ntr) domain containing protein
JP2005507631A (ja) 新規ヒトｎ末端アセチルトランスフェラーゼの同定
WO2007010283A1 (en) Serine beta-lactamase-like / d-ala carboxypeptidase-like protein
WO2007071992A1 (en) Casein-like secreted protein
WO2007113488A1 (en) Fibronectin type iii domain containing protein
WO2007045911A1 (en) Integral membrane protein

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1120048

Country of ref document: HK

AD01 Patent right deemed abandoned

Effective date of abandoning: 20080528

C20 Patent right or utility model deemed to be abandoned or is abandoned
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1120048

Country of ref document: HK